Country: United States
Language: English
Source: NLM (National Library of Medicine)
ERLOTINIB HYDROCHLORIDE (UNII: DA87705X9K) (ERLOTINIB - UNII:J4T82NDH7E)
Armas Pharmaceuticals Inc.
ORAL
PRESCRIPTION DRUG
Erlotinib Tablets was indicated for: - The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen [see Clinical Studies (14.1 , 14.3)] . Limitations of use: - Safety and efficacy of erlotinib have not been established in patients with NSCLC whose tumors have other EGFR mutations [see Clinical Studies(14.1,14.2)]. - Erlotinib tablet is not recommended for use in combination with platinum-based chemotherapy [see Clinical Studies (14.4)]. Erlotinib tablet in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer [see Clinical Studies (14.5)] . None Based on animal data and its mechanism of action, erlotinib tablets
25 mg Tablets: White to off white round, biconvex film-coated tablets, debossed with “S13” on one side and plain on other side. Supplied in: Bottles of 30: NDC 72485-217-30 100 mg Tablets: White to off white round, biconvex film-coated tablets, debossed with “S12” on one side and plain on other side. Supplied in: Bottles of 30: NDC 72485-218-30 150 mg Tablets: White to off white round, biconvex film-coated tablets, debossed with “S11” on one side and plain on other side. Supplied in: Bottles of 30: NDC 72485-219-30 Store at 25°C (77°F); excursions permitted to 15°C -30°C (59°F -86°F). [See USP Controlled Room Temperature].
Abbreviated New Drug Application
ERLOTINIB- ERLOTINIB HYDROCHLORIDE TABLET, FILM COATED ARMAS PHARMACEUTICALS INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ERLOTINIB TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ERLOTINIB TABLETS. ERLOTINIB TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2004 INDICATIONS AND USAGE Erlotinib tablet is a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving rst-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen (1.1) First-line treatment of patients with locally advanced, unrespectable or metastatic pancreatic cancer, in combination with gemcitabine. (1.2) Limitations of Use: Safety and efcacy of erlotinib tablets have not been established in patients with NSCLC whose tumors have other EGFR mutations. (1.1) Erlotinib tablets are not recommended for use in combination with platinum-based chemotherapy. (1.1) DOSAGE AND ADMINISTRATION NSCLC: 150mg orally, on an empty stomach, once daily (2.2) Pancreatic cancer: 100 mg orally, on an empty stomach, once daily. (2.3) DOSAGE FORMS AND STRENGTHS Tablets: 25mg, 100mg and 150mg (3) (3) CONTRAINDICATIONS None (4) WARNINGS AND PRECAUTIONS Interstitial lung disease (ILD): Occurs in 1.1% of patients. Withhold erlotinib tablets for acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever. Discontinue erlotinib if ILD is diagnosed. (5.1) Renal failure: Monitor renal function and electrolytes, particularly in patients at risk of dehydration. Withhold erlotinib tablets for severe renal toxicity. (5.2) Hepatotoxicity: Occurs with or without hepatic impairment, including hepatic failure and hepatorenal syndrome: Monitor periodic liver testing. Withhold or dis Read the complete document